REQAAP (Repeated QUTENZA Application to Alleviate Pain)

A Post-Market Observational Multi-Center Study to Evaluate the Effectiveness of Repeated QUTENZA Use in Adults with Painful Diabetic Peripheral Neuropathy of the Feet

Drug: QUTENZA (capsaicin 8% topical system)

The patients for inclusion in the study are those with Painful Diabetic Peripheral Neuropathy (PDPN) of the feet as assessed by the Douleur Neuropathique 4 Interview (DN4I) assessment.

The study takes place over approximately 36-weeks and includes up to 3 applications.

Participation Criteria: CLICK HERE

Shiratronics RELIEV-CM2

A Pivotal Study Evaluating Safety and Efficacy of the Shiratronics Migraine Therapy System in Relieving, Interrupting, and Preventing Chronic Migraine

Device: Neurostimulator

The ShiraTronics Migraine Therapy System is indicated for prophylactic treatment of patients with refractory chronic migraine

Subjects will be enrolled, implanted and randomized to either high or low dose stimulation in a 1:1 ratio. Visits will include a 28-day headache diary screening period, baseline, trial stimulation phase, implant, randomization, and 2, 4, 8,12,16, 20 and 24- weeks post-randomization, 9 and 12- months post trial implant date.

Participation Criteria: CLICK HERE

Additional Trial Information: CLICK HERE

CornerLoc SPARTAN

Post-Market Clinical Study on a Modular SI Joint Fusion System

Device: TransLoc 3D

For patients with sacroiliac joint disruptions or degenerative sacroiliitis.

Follow-up occurs at 6-, 12-, and 24-months

Participation Criteria: CLICK HERE